Allogene Therapeutics Current Valuation vs. EBITDA

ALLO Stock  USD 2.02  0.12  5.61%   
Based on Allogene Therapeutics' profitability indicators, Allogene Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Allogene Therapeutics' ability to earn profits and add value for shareholders. At this time, Allogene Therapeutics' Price To Sales Ratio is very stable compared to the past year. As of the 13th of December 2024, EV To Sales is likely to grow to 5,700, while Operating Cash Flow Sales Ratio is likely to drop (2.6 K). At this time, Allogene Therapeutics' Total Other Income Expense Net is very stable compared to the past year. As of the 13th of December 2024, Interest Income is likely to grow to about 15.5 M, while Accumulated Other Comprehensive Income is likely to drop (1 M).
For Allogene Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Allogene Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Allogene Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Allogene Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Allogene Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.55)
Quarterly Revenue Growth
(0.27)
Return On Assets
(0.26)
Return On Equity
(0.54)
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Allogene Therapeutics EBITDA vs. Current Valuation Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Allogene Therapeutics's current stock value. Our valuation model uses many indicators to compare Allogene Therapeutics value to that of its competitors to determine the firm's financial worth.
Allogene Therapeutics is rated below average in current valuation category among its peers. It is rated below average in ebitda category among its peers . Allogene Therapeutics reported last year EBITDA of (300.29 Million). The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Allogene Therapeutics' earnings, one of the primary drivers of an investment's value.

Allogene Current Valuation vs. Competition

Allogene Therapeutics is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is presently estimated at about 14.96 Billion. Allogene Therapeutics claims roughly 242.27 Million in current valuation contributing just under 2% to equities under Health Care industry.

Allogene EBITDA vs. Current Valuation

Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Allogene Therapeutics

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
242.27 M
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Allogene Therapeutics

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(300.29 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Allogene EBITDA Comparison

Allogene Therapeutics is currently under evaluation in ebitda category among its peers.

Allogene Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Allogene Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Allogene Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Allogene Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Allogene Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-955 K-1 M
Operating Income-327.7 M-344.1 M
Net Loss-332.9 M-349.5 M
Income Before Tax-327.3 M-343.6 M
Total Other Income Expense Net472 K938.1 K
Net Loss-299.4 M-314.3 M
Net Loss-327.3 M-343.6 M
Income Tax Expense-2.5 M-2.7 M
Net Interest Income14.8 M9.2 M
Interest Income14.8 M15.5 M
Non Operating Income Net Other-1.4 M-1.3 M
Change To Netincome84.7 M76.9 M
Net Loss(2.09)(2.19)
Income Quality 0.73  0.47 
Net Income Per E B T 1.14  1.07 

Allogene Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Allogene Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Allogene Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Allogene Therapeutics' important profitability drivers and their relationship over time.

Use Allogene Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allogene Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allogene Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Allogene Therapeutics Pair Trading

Allogene Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Allogene Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allogene Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allogene Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allogene Therapeutics to buy it.
The correlation of Allogene Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allogene Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allogene Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allogene Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Allogene Therapeutics position

In addition to having Allogene Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Data Storage Thematic Idea Now

Data Storage
Data Storage Theme
Companies making data storages or providing data storage services. The Data Storage theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Data Storage Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Allogene Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Allogene Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Allogene Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Allogene Therapeutics Stock:
Check out Trending Equities.
To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
To fully project Allogene Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Allogene Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Allogene Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential Allogene Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Allogene Therapeutics investors may work on each financial statement separately, they are all related. The changes in Allogene Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Allogene Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.